Literature DB >> 1309784

A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor.

H Ueno1, M Gunn, K Dell, A Tseng, L Williams.   

Abstract

A truncated form of the type 1 fibroblast growth factor receptor (FGFR1) lacking most of its cytoplasmic domain was tested for its ability to inhibit signal transduction by each of three different wild-type FGFRs (FGFR1, 2, and 3). When the truncated FGFR1 was expressed in Xenopus oocytes in excess of each wild-type FGFR, mobilization of intracellular calcium mediated by the wild-type FGFRs was completely blocked. The truncated FGFR did not inhibit signal transduction by the co-expressed platelet-derived growth factor beta-receptor. A form of truncated FGFR1 which lacked the first immunoglobulin-like domain also inhibited signal transduction by wild-type FGFRs. Truncated FGFR formed complexes with wild-type FGFR in the presence of basic FGF in intact cells. These observations were consistent with the hypothesis that the truncated FGFR interacted with wild-type FGFRs to form nonfunctional heterodimers, thus eliminating the signaling by the wild-type FGFRs. The observation that signaling by multiple types of FGFR can be blocked by a single type of truncated FGFR suggests that the different types of FGFR can interact with each other in ligand-mediated complexes. These findings provide a molecular basis for inhibiting the actions of FGFs in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309784

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Fgfr2 is required for limb outgrowth and lung-branching morphogenesis.

Authors:  E Arman; R Haffner-Krausz; M Gorivodsky; P Lonai
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  In vivo modulation of FGF biological activity alters cranial suture fate.

Authors:  J A Greenwald; B J Mehrara; J A Spector; S M Warren; P J Fagenholz; L E Smith; P J Bouletreau; F E Crisera; H Ueno; M T Longaker
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans.

Authors:  J C Davis; G Venkataraman; Z Shriver; P A Raj; R Sasisekharan
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

Review 4.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 5.  A role for fibroblast growth factor signaling in the lobuloalveolar development of the mammary gland.

Authors:  D Jackson; J Bresnick; C Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

6.  FGF-dependent regulation of VEGF receptor 2 expression in mice.

Authors:  Masahiro Murakami; Loc T Nguyen; Kunihiko Hatanaka; William Schachterle; Pei-Yu Chen; Zhen W Zhuang; Brian L Black; Michael Simons
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

7.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

8.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.

Authors:  Dhruba J Bharali; Ilona Klejbor; Ewa K Stachowiak; Purnendu Dutta; Indrajit Roy; Navjot Kaur; Earl J Bergey; Paras N Prasad; Michal K Stachowiak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

9.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

Authors:  F Yamaguchi; H Saya; J M Bruner; R S Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Authors:  Michael G Gartside; Huaibin Chen; Omar A Ibrahimi; Sara A Byron; Amy V Curtis; Candice L Wellens; Ana Bengston; Laura M Yudt; Anna V Eliseenkova; Jinghong Ma; John A Curtin; Pilar Hyder; Ursula L Harper; Erica Riedesel; Graham J Mann; Jeffrey M Trent; Boris C Bastian; Paul S Meltzer; Moosa Mohammadi; Pamela M Pollock
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.